PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 207 (xsd:integer)
nif:isString
  • Clinical trials investigating the use of PARP inhibitors in patients with metastatic BC and somatic or germline BRCA2 or other DDR mutations are currently ongoing (NCT03397394, NCT03448718, and NCT03375307).
rdf:type